Menarini Group acquires Stemline Therapeutics for $677M.
“Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world.”
Elcin Barker Ergun, CEO of Menarini Group
Through this acquisition Menarini will provide the infrastructure allowing Stemline to help those with difficult to treat diseases and cancers.